Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

NCT06139575 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Lutetium Lu 177 JH020002 Injection

Sponsor

Bivision Pharmaceuticals, Inc.